Time spent at blood pressure target and the risk of death and cardiovascular diseases

• Published in: PloS one 2018-09, Vol.13 (9), p.e0202359-e0202359
• Main Authors: Chung, Sheng-Chia, Pujades-Rodriguez, Mar, Duyx, Bram, Denaxas, Spiros C, Pasea, Laura, Hingorani, Aroon, Timmis, Adam, Williams, Bryan, Hemingway, Harry
• Format: Article
• Language: English
• Subjects: Adult; Aged; Anticoagulants; Antihypertensive Agents - therapeutic use; Biomedical research; Blood; Blood pressure; Blood Pressure - drug effects; Blood Pressure Determination; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - mortality; Cardiovascular Diseases - physiopathology; Cardiovascular Diseases - prevention & control; Cerebral infarction; Clinical trials; Cohort Studies; Confidence intervals; Control; Death; Diabetes; Electronic health records; Fatalities; Female; Health aspects; Health informatics; Health risk assessment; Health risks; Heart attacks; Heart diseases; Heart failure; Hospitals; Humans; Hypertension; Hypertension - drug therapy; Hypertension - physiopathology; Lifestyles; Male; Medical research; Medicine and Health Sciences; Middle Aged; Mortality; Myocardial infarction; Patient outcomes; Patients; Population; Population studies; Primary care; Risk Factors; Survival Rate; Time Factors
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0202359

The time a patient spends with blood pressure at target level is an intuitive measure of successful BP management, but population studies on its effectiveness are as yet unavailable. We identified a population-based cohort of 169,082 individuals with newly identified high blood pressure who were free of cardiovascular disease from January 1997 to March 2010. We used 1.64 million clinical blood pressure readings to calculate the TIme at TaRgEt (TITRE) based on current target blood pressure levels. The median (Inter-quartile range) TITRE among all patients was 2.8 (0.3, 5.6) months per year, only 1077 (0.6%) patients had a TITRE ≥11 months. Compared to people with a 0% TITRE, patients with a TITRE of 3-5.9 months, and 6-8.9 months had 75% and 78% lower odds of the composite of cardiovascular death, myocardial infarction and stroke (adjusted odds ratios, 0.25 (95% confidence interval: 0.21, 0.31) and 0.22 (0.17, 0.27), respectively). These associations were consistent for heart failure and any cardiovascular disease and death (comparing a 3-5.9 month to 0% TITRE, 63% and 60% lower in odds, respectively), among people who did or did not have blood pressure 'controlled' on a single occasion during the first year of follow-up, and across groups defined by number of follow-up BP measure categories. Based on the current frequency of measurement of blood pressure this study suggests that few newly hypertensive patients sustained a complete, year-round on target blood pressure over time. The inverse associations between a higher TITRE and lower risk of incident cardiovascular diseases were independent of widely-used blood pressure 'control' indicators. Randomized trials are required to evaluate interventions to increase a person's time spent at blood pressure target.